168 related articles for article (PubMed ID: 35976466)
1. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver.
Frigerio I; Malleo G; de Pastena M; Deiro G; Surci N; Scopelliti F; Esposito A; Regi P; Giardino A; Allegrini V; Bassi C; Girelli R; Salvia R; Butturini G
Ann Surg Oncol; 2022 Dec; 29(13):8503-8510. PubMed ID: 35976466
[TBL] [Abstract][Full Text] [Related]
2. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
3. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
[TBL] [Abstract][Full Text] [Related]
4. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
6. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma.
Crippa S; Pergolini I; Javed AA; Honselmann KC; Weiss MJ; Di Salvo F; Burkhart R; Zamboni G; Belfiori G; Ferrone CR; Rubini C; Yu J; Gasparini G; Qadan M; He J; Lillemoe KD; Castillo CF; Wolfgang CL; Falconi M
Ann Surg; 2022 Aug; 276(2):378-385. PubMed ID: 33086324
[TBL] [Abstract][Full Text] [Related]
7. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
9. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
10. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
Tachezy M; Gebauer F; Janot M; Uhl W; Zerbi A; Montorsi M; Perinel J; Adham M; Dervenis C; Agalianos C; Malleo G; Maggino L; Stein A; Izbicki JR; Bockhorn M
Surgery; 2016 Jul; 160(1):136-144. PubMed ID: 27048934
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma.
Abe T; Nakata K; Kibe S; Mori Y; Miyasaka Y; Ohuchida K; Ohtsuka T; Oda Y; Nakamura M
Ann Surg Oncol; 2018 Dec; 25(13):3996-4003. PubMed ID: 30225838
[TBL] [Abstract][Full Text] [Related]
12. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
13. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy.
Crippa S; Cirocchi R; Weiss MJ; Partelli S; Reni M; Wolfgang CL; Hackert T; Falconi M
Updates Surg; 2020 Mar; 72(1):39-45. PubMed ID: 31997233
[TBL] [Abstract][Full Text] [Related]
15. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients.
Nagai M; Wright MJ; Ding D; Thompson ED; Javed AA; Weiss MJ; Hruban RH; Yu J; Burkhart RA; He J; Cameron JL; Wolfgang CL; Burns WR
J Hepatobiliary Pancreat Sci; 2023 Aug; 30(8):1025-1035. PubMed ID: 36652559
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
17. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
20. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
